Search Results

MGC Pharmaceuticals Ltd, Rebrands as Argent BioPharma in Strategic Transformation Marking a significant milestone in its evolutionary journey, MGC Pharma has officially announced its rebranding to Argent BioPharma, pending approval from its shareholders.

Portfolio Expands to Include Non-Invasive Cardiorespiratory Diagnostic Systems CAIRE Inc., a subsidiary of NGK SPARK PLUG CO., LTD., will acquire St. Paul, Minnesota-based MGC Diagnostics Holdings, Inc. MGC designs, develops, manufactures, and markets non-invasive cardiorespiratory diagnostic systems, accessories, and consumables for the detection, classification, and management of cardiorespiratory disease.

Quest Diagnostics, a leader in diagnostic information services, released its 2023 Corporate Responsibility Report.

MGC Diagnostics Corporation (“MGC”), a global medical technology company dedicated to cardiorespiratory health solutions, and a portfolio company of Altus Capital Partners, Inc. (“Altus”), announced today the acquisition of Lemon Medical, GmbH.

MGC Pharmaceuticals Ltd., announces that its proprietary product CannEpil® is now available to patients in the UK by Named Patient Request.

Ending the diagnostic journey for patients, particularly those with rare diseases, improves patients’ quality of life while reducing costs to healthcare systems.

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter, a seasoned technology executive, to serve as a director.

C₂N Diagnostics, LLC announced a partnership agreement with Mediford Corporation, a PHC Holdings Corporation Group Company and premier provider of clinical research to the biopharma industry throughout Japan.